Abstract
SUMMARY: Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.
Abbreviations
- EGFR
- epidermal growth factor receptor
- FDA
- US Food and Drug Administration
- HER
- human epidermal growth factor receptor
- SCC
- squamous cell carcinoma
- SCCHN
- SCC of the head and neck
- Copyright © American Society of Neuroradiology
In this issue
Cetuximab (Erbitux)
Jump to section
Related Articles
Cited By...
- No citing articles found.